Clinical case of treatment of patient with HRD-positive ovarian cancer
- 作者: Khokhlova S.V.1
-
隶属关系:
- National Medical Research Center for Obstetrics, Gynecology and Perinatology n.a. Academician V.I. Kulakov
- 期: 卷 28, 编号 11 (2021)
- 页面: 96-104
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313282
- DOI: https://doi.org/10.18565/pharmateca.2021.11.96-104
- ID: 313282
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Background. Ovarian cancer (OC) is the leading cause of death from oncogynecological diseases in the world [1]. In almost 75% of women with OC, the disease is detected at a late stage. Description of the clinical case. Patient T., born in 1970, was admitted for treatment in February 2019 with a diagnosis of IIIC stage ovarian cancer. From February 2019 to April 2019, 4 courses of chemotherapy were carried out: paclitaxel 175 mg/m2+carboplatin AUC6+bevacizumab 7.5 mg/kg every 21 days. In April 2019, an optimal volume of interval cytoreduction was performed. Since September 2019, olaparib 300 mg 2 times a day has been added to bevacizumab. According to computed tomography data from 2020 and September 2021, complete remission remains. Conclusion. Olaparib is the first PARP inhibitor approved by FDA (Food and Drug Administration) for maintenance treatment as monotherapy or in combination with bevacizumab for patients with newly diagnosed OC, and this event over the past several decades has led to a major breakthrough in the standard of care for patients with OC.
全文:
作者简介
Svetlana Khokhlova
National Medical Research Center for Obstetrics, Gynecology and Perinatology n.a. Academician V.I. Kulakov
Email: svkhokhlova@mail.m
Dr. Sci. (Med.), Oncologist-Chemotherapist, Head of the Oncology Department ofAnticancer Drug Therapy Moscow, Russia
参考
- Cancer Statistics Center. American Cancer Society Web site. Updated 2020. Available at: https://cancerstatisticscenter.cancer.org (Accessed May 11, 2020).
- Hennessy B.T., Coleman R.L., Markman M. Ovarian cancer. Lancet. 2009;374:1371-82. doi: 10.1016/S0140-6736(09)61338-6.
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30. doi: 10.3322/caac.21442.
- Miki Y, Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-doi: 10.1126/science.7545954.
- Ledermann J.A. PARP inhibitors in ovarian cancer. Ann Oncol. 2016;27(Suppl. 1):i40-4. doi: 10.1093/annonc/mdw094.
- Kuchenbaecker K.B., Hopper J.L., Barnes D.R., et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402-16. Doi: 10.1001/ jama.2017.7112.
- Pennington K.P., Walsh T., Harrell M.I., et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20:764-75. doi: 10.1158/1078-0432.CCR-13-2287.
- Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15. doi: 10.1038/nature10166.
- Polterauer S., Vergote I., Concin N., et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: Analysis of the OVCAD data. Int J Gynecol Oncol. 2012;22:380-85. Doi: 10.1097/ IGC.0b013e31823de6ae.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 1.2020. Plymouth Meeting, PA: National Comprehensive Cancer Network, 2020. Available at: https:// www.nccn.org/professionals/physician_gls/pdf/ovarian. pdf (Accessed May 11, 2020)
- Burger R.A., Brady M.F., Bookman M.A., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-83. Doi: 10.1056/ NEJMoa1104390.
- Avastin [package insert]. South San Francisco, CA: Genentech, Inc., June 2019.
- Ledermann J.A., Raja F.A., Fotopoulou C., et al.; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi24-32. doi: 10.1093/annonc/mdt333.
- Lynparza [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP May 2020.
- Kim G., Ison G., McKee A.E., et al. FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015;21:4257-doi: 10.1158/1078-0432.CCR-15-0887.
- Dougherty B.A., Lai Z., Hodgson D.R., et al. Biological and clinical evidence for somatic mutations in BRCA 1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget. 2017;8:43653-61. Doi: 10.18632/ oncotarget.17613.
- Hennessy B.T., Timms K.M., Carey M.S., et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP Ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28:3570-76. doi: 10.1200/JCO.2009.27.2997
补充文件
